为GMP原料设计稳健取样计划的方法与监管依据梳理

Designing a Robust Sampling Plan for GMP Raw Materials
为GMP原料设计稳健的取样计划

In pharmaceutical manufacturing, prioritizing the quality and safety of products is essential, with rigorous sampling of raw materials serving as the initial step.
在制药生产中，优先考虑产品质量和安全至关重要，而严格的原料取样是第一步。

Mastery of Good Manufacturing Practices (GMP) serves as a fundamental element for upholding high standards, yet complexity arises when navigating regulatory expectations and compliance.
掌握药品生产质量管理规范（GMP）是维持高标准的基本要素，但在应对监管期望和合规时会出现复杂性。

This article examines the multifaceted components involved in designing a robust sampling plan for GMP raw materials.
本文探讨为GMP原料设计稳健取样计划所涉及的多方面组成部分。

It is imperative for manufacturers to align their practices with the guidelines established by regulatory bodies, such as the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).
生产商必须使其实践符合欧洲药品管理局（EMA）和美国食品药品监督管理局（FDA）等监管机构制定的指南。

By evaluating various types of sampling plans—including acceptance, attribute, variable, and stratified sampling plans—manufacturers can customize their approaches to ensure both compliance and optimal quality.
通过评估各类取样计划——包括验收取样、计数型取样、计量型取样和分层取样计划——生产商可以定制其方法，以确保合规和最佳质量。

Additionally, understanding material considerations, from active ingredients to packaging materials, is vital in identifying and effectively addressing specific challenges.
此外，理解从活性成分到包装材料的物料考虑因素，对于识别并有效处理特定挑战至关重要。

Focusing on integrating a lifecycle approach and employing risk-based techniques, this article underscores the importance of process validation and necessary tools for effective sampling.
本文聚焦于整合生命周期方法和采用基于风险的技术，强调工艺验证和有效取样所需工具的重要性。

From the design of sampling booths to quality management principles, the strategies outlined aim to mitigate risks, ensure product integrity, and ultimately safeguard patient safety.
从取样间设计到质量管理原则，所概述的策略旨在减轻风险、确保产品完整性，并最终保护患者安全。

As we explore techniques and best practices, we will demonstrate how a robust sampling plan not only aligns with regulatory requirements but also maintains efficacy and safety in pharmaceutical manufacturing.
当我们探索技术和最佳实践时，我们将展示稳健的取样计划如何不仅符合法规要求，还维持制药生产中的有效性和安全性。

Understanding Good Manufacturing Practices (GMP)
理解药品生产质量管理规范（GMP）

Good Manufacturing Practice (GMP) regulations are crucial for ensuring product quality and consistency in manufacturing processes.
药品生产质量管理规范（GMP）法规对于确保制造过程中的产品质量和一致性至关重要。

These regulations require scientifically justified and statistically valid processes.
这些法规要求科学合理且统计有效的过程。

A GMP-compliant sampling plan is essential in this context, offering representative data that aids in making informed decisions about material or product acceptance or rejection.
在此背景下，符合GMP的取样计划至关重要，它提供代表性数据，有助于就物料或产品的接受或拒绝做出明智决策。

The key components of such a plan include:
此类计划的关键组成部分包括：

Sampling Methods: Methods such as random and stratified sampling reduce bias and ensure representation based on material type, process, and regulatory needs.
取样方法：随机取样和分层取样等方法可减少偏倚，并根据物料类型、工艺和监管需求确保代表性。

Sample Size and Frequency: These are determined to provide statistical validity to the findings.
样本量和频率：确定这些是为了使发现具有统计有效性。

Sampling Location: Chosen to ensure the sample is representative of the whole batch.
取样位置：选择以确保样品代表整批。

Acceptance Criteria: Clearly defined to assess if the raw materials meet the required quality standards.
接受标准：明确定义，以评估原料是否符合所需质量标准。

The primary goals of a GMP sampling plan align with compliance to regulatory standards such as those set by the FDA and EMA.
GMP取样计划的主要目标与符合FDA和EMA等制定的监管标准一致。

These plans aim to minimize risks and support continuous improvement and risk management initiatives.
这些计划旨在最大限度降低风险，并支持持续改进和风险管理举措。

By adhering to these principles, companies ensure that their manufacturing processes are both compliant and capable of consistently producing high-quality products.
通过遵守这些原则，公司确保其制造过程既合规，又能持续生产高质量产品。

Regulatory Expectations and Compliance
监管期望与合规

In the pharmaceutical industry, regulatory authorities like the FDA and EMA set stringent standards for manufacturing processes, particularly focusing on the incorporation of scientifically justified and statistically valid sampling plans.
在制药行业，FDA和EMA等监管机构为制造过程设定严格标准，尤其关注纳入科学合理且统计有效的取样计划。

These expectations are crucial for ensuring the quality and safety of medicinal products, especially given the risks associated with contamination from substances like diethylene glycol (DEG) or ethylene glycol (EG).
这些期望对于确保药品质量和安全至关重要，尤其是考虑到二甘醇（DEG）或乙二醇（EG）等物质污染相关风险。

Regulatory guidelines advocate for a risk-based approach in testing raw materials to prevent such contamination.
监管指南倡导在原料检测中采用基于风险的方法，以防止此类污染。

As stipulated in the EU Good Manufacturing Practice (GMP) guidelines, particularly Chapter 5, manufacturers must verify the identity and quality of all raw materials upon receipt.
如欧盟药品生产质量管理规范（GMP）指南（尤其是第5章）所规定，生产商必须在收到所有原料时验证其鉴别和质量。

This involves comparing the manufacturer's certificate of analysis with raw material specifications to ensure compliance.
这涉及将生产商的分析证书与原料规格进行比较，以确保合规。

Sampling plans under GMP are not only preventative but also essential to meeting regulatory, scientific, and statistical expectations.
GMP下的取样计划不仅是预防性的，也是满足监管、科学和统计期望的必要条件。

Overview of EMA Guidelines
EMA指南概述

The European Medicines Agency (EMA) provides detailed guidance for pharmaceutical manufacturers, emphasizing a life-cycle approach to process validation.
欧洲药品管理局（EMA）为制药生产商提供详细指南，强调工艺验证的生命周期方法。

This approach integrates Quality by Design (QbD), risk management, and continuous process verification to ensure that manufacturing processes remain under control from start to finish.
该方法整合质量源于设计（QbD）、风险管理和持续工艺确认，以确保制造过程从头到尾处于受控状态。

A pivotal document, EMA/CHMP/CVMP/QWP/70278/2012-Rev1, Corr.1, outlines the agency's expectations for the validation of manufacturing processes, ensuring they meet high standards of quality and safety.
关键文件 EMA/CHMP/CVMP/QWP/70278/2012-Rev1, Corr.1 概述了该机构对制造工艺验证的期望，确保其符合高质量和安全标准。

Annex 15 of the EU GMP guidelines is another critical resource, detailing requirements for the qualification and validation of processes.
EU GMP 指南附录 15是另一个关键资源，详细说明工艺确认和验证的要求。

Furthermore, EudraLex Volume 4, Annex 8, emphasizes the importance of sampling individual containers to confirm the identity of a complete batch of starting materials.
此外，EudraLex 第4卷附录 8强调对单个容器取样以确认整批起始物料鉴别的重要性。

The EMA has also issued questions and answers documents addressing exemptions from batch controls for Advanced Therapy Medicinal Products (ATMPs) imported into the EU, highlighting the agency's adaptable approach to evolving pharmaceutical technologies and practices.
EMA还发布了问答文件，处理进口到欧盟的先进治疗药品（ATMP）批次控制豁免问题，突显该机构对不断演变的制药技术和实践的适应性方法。

Overview of FDA Guidelines
FDA指南概述

In the realm of GMP-regulated industries, adhering to FDA guidelines is fundamental to ensuring both product quality and regulatory compliance.
在GMP监管行业领域，遵守FDA指南是确保产品质量和法规合规的基础。

The FDA's guidelines are focused on creating robust sampling plans that align with their scientific and statistical standards for quality assurance.
FDA指南侧重于制定稳健取样计划，使其符合其质量保证的科学和统计标准。

Key objectives of these guidelines include mitigating risks of batch rejection, minimizing product recalls, and fostering continuous improvement and risk management within manufacturing processes.
这些指南的主要目标包括减轻批次拒绝风险、最大限度减少产品召回，并促进制造过程中的持续改进和风险管理。

A compliant sampling plan according to the FDA encompasses well-defined elements such as the sampling method, sample size, frequency, location, acceptance criteria, and rationale for strategy selection.
根据FDA，合规取样计划包含明确定义的要素，如取样方法、样本量、频率、位置、接受标准以及策略选择理由。

The agency places a strong emphasis on scientifically-based sampling techniques, such as random or stratified sampling, to minimize bias and ensure comprehensive material representation.
该机构强烈强调基于科学的取样技术，如随机或分层取样，以最大限度减少偏倚并确保全面的物料代表性。

In addition, verifying that raw materials adhere to FDA standards often involves validating suppliers and conducting identity testing on every container of active raw materials unless the supplier is pre-validated.
此外，验证原料符合FDA标准通常涉及供应商确认，并对每容器活性原料进行鉴别检测，除非供应商已经过预先确认。

These practices underline the agency's commitment to maintaining high standards for product integrity and public health safety.
这些实践强调该机构对维持产品完整性和公共卫生安全高标准的承诺。

Types of Sampling Plans
取样计划类型

In Good Manufacturing Practice (GMP)-regulated industries, the design of sampling plans is crucial to ensure the quality and consistency of raw materials.
在药品生产质量管理规范（GMP）监管行业中，取样计划的设计对于确保原料质量和一致性至关重要。

A compliant sampling plan incorporates several elements including sampling method, sample size, frequency, and location, alongside well-defined acceptance criteria.
合规取样计划包含若干要素，包括取样方法、样本量、频率和位置，以及明确定义的接受标准。

These plans are grounded in scientific or risk-based justifications to maintain statistical validity.
这些计划以科学或基于风险的理由为基础，以维持统计有效性。

Sampling plans play a vital role in achieving regulatory compliance, minimizing risks associated with batch rejection or product recalls, and supporting ongoing improvement and risk management.
取样计划在实现法规合规、最大限度降低批次拒绝或产品召回相关风险，以及支持持续改进和风险管理方面发挥重要作用。

Depending on the raw material type, processing stages, and regulatory expectations, various sampling techniques like random sampling can help minimize bias and guarantee that samples are representative of the entire population.
根据原料类型、加工阶段和监管期望，随机取样等各种取样技术有助于最大限度减少偏倚，并保证样品代表整个总体。

Acceptance Sampling Plans
验收取样计划

Acceptance sampling plans are a fundamental component in ensuring the quality and consistency of raw materials and finished products within GMP environments.
验收取样计划是确保GMP环境中原料和成品质量和一致性的基本组成部分。

These plans allow manufacturers to decide whether to accept or reject a batch based on the inspection of a defined number of units.
这些计划使生产商能够根据对规定数量单位的检查来决定接受或拒绝一批。

They are an integral part of GMP compliance, well-aligned with guidelines from regulatory authorities such as the FDA and EMA.
它们是GMP合规不可或缺的一部分，与FDA和EMA等监管机构的指南高度一致。

Acceptance sampling plans utilize statistically motivated methods to determine the sample sizes and acceptance criteria.
验收取样计划利用统计驱动方法确定样本量和接受标准。

Standards like ANSI/ASQ Z1.4 and ISO 2859 often guide these methodologies.
ANSI/ASQ Z1.4和ISO 2859等标准通常指导这些方法。

Furthermore, these plans must incorporate sampling frequency, location, and robust scientific justification for the selected approaches.
此外，这些计划必须纳入取样频率、位置以及所选方法的稳健科学理由。

Depending on the type of material and specific process, different sampling methods like random and stratified sampling may be employed to ensure compliance with regulatory standards.
根据物料类型和特定工艺，可能采用随机取样和分层取样等不同取样方法，以确保符合监管标准。

Attribute Sampling Plans
计数型取样计划

Attribute sampling plans provide a statistically valid method to determine appropriate sample sizes based on the total population or batch size, ensuring stringent quality controls.
计数型取样计划提供统计有效方法，根据总体或批量确定适当样本量，确保严格质量控制。

One of the most common strategies employed in attribute sampling plans is the Sqrt(N) + 1 formula, which helps determine the necessary sample size to assess the quality of a batch.
计数型取样计划中最常用的策略之一是 Sqrt(N) + 1 公式，有助于确定评估批次质量所需样本量。

In these plans, the acceptance number (Ac) is often set to zero while the rejection number (Re) is set to one, reflecting a strict quality assurance approach.
在这些计划中，接受数（Ac）通常设为零，而拒绝数（Re）设为一，反映严格质量保证方法。

Tools like Table X-G can be applied to analyze acceptance probabilities, providing a clear acceptable quality level (AQL).
Table X-G 等工具可用于分析接受概率，提供清晰的可接受质量水平（AQL）。

The creation of an operating characteristic (OC) curve is also part of these plans, calculated to define the performance and efficacy of the sampling regimen.
操作特性（OC）曲线的创建也是这些计划的一部分，计算以定义取样方案的性能和效力。

This approach ensures that each sample taken truly represents the quality of the entire batch, maintaining the integrity of the manufacturing process.
这种方法确保所取每个样品真正代表整批质量，维护制造过程的完整性。

Variable Sampling Plans
计量型取样计划

In GMP-regulated environments, variable sampling plans are designed to deliver representative data for quality assurance, enabling manufacturers to make informed decisions regarding raw materials.
在GMP监管环境中，计量型取样计划旨在为质量保证提供代表性数据，使生产商能够就原料做出明智决策。

A robust variable sampling plan typically includes methods of sampling, sample size, sampling frequency, location, and clear acceptance criteria.
稳健的计量型取样计划通常包括取样方法、样本量、取样频率、位置和明确接受标准。

Justification for the strategies used is also crucial.
所用策略的理由也至关重要。

Variable plans often employ methodologies such as random and stratified sampling to effectively reduce bias and assure representative material selection.
计量型计划通常采用随机和分层取样等方法，以有效减少偏倚并确保代表性物料选择。

The standards provided by ANSI/ASQ Z1.4 and ISO 2859 are pivotal in the determination of sample sizes, thereby enhancing the statistical reliability of these plans.
ANSI/ASQ Z1.4和ISO 2859提供的标准在确定样本量方面至关重要，从而增强这些计划的统计可靠性。

By adhering to these standards, manufacturers can ensure that the samples are indicative of the overall batch, thereby contributing to product quality and regulatory compliance.
通过遵守这些标准，生产商可以确保样品代表整体批次，从而有助于产品质量和法规合规。

Stratified Sampling Plans
分层取样计划

Stratified sampling is an essential approach in designing sampling plans for GMP-regulated industries, aiming to maximize representation across the population by dividing it into distinct subgroups and selecting samples from each.
分层取样是GMP监管行业设计取样计划的重要方法，旨在通过将总体划分为不同子组并从每个子组中选取样品，最大限度提高代表性。

This method ensures that every segment of the population is proportionally included, reducing potential bias and enhancing the quality assurance process.
该方法确保总体每个部分按比例纳入，减少潜在偏倚并增强质量保证过程。

It forms part of a robust sampling plan tailored to meet regulatory compliance and ensure high product quality standards.
它构成稳健取样计划的一部分，旨在满足法规合规并确保高产品质量标准。

Stratified sampling can be particularly useful across various material types and processing stages, aligning with regulatory needs.
分层取样在各种物料类型和加工阶段尤其有用，符合监管需求。

By dividing the lot into these subgroups, sampling plans using stratification can address specific variability within the population, ensuring that the final product meets the stringent requirements set by regulatory bodies.
通过将批次划分为这些子组，使用分层的取样计划可以处理总体内的特定变异性，确保最终产品符合监管机构制定的严格要求。

Material Considerations in Sampling
取样中的物料考虑

Designing a statistically valid sampling plan for raw materials in GMP manufacturing is essential to ensure consistency, quality, and compliance with regulatory expectations.
为GMP生产中的原料设计统计有效的取样计划，对于确保一致性、质量和符合监管期望至关重要。

A well-documented sampling plan within a quality management system outlines the method, quantity, frequency, and location of sampling for materials, components, or products.
质量管理体系内记录完善的取样计划概述物料、组件或产品的取样方法、数量、频率和位置。

It guarantees adherence to Good Manufacturing Practice (GMP) and other regulatory standards such as those set by the European Pharmacopoeia and the World Health Organization.
它保证遵守药品生产质量管理规范（GMP）以及欧洲药典和世界卫生组织等制定的其他监管标准。

Critical factors in formulating such plans include selecting the appropriate sampling method, determining the sample size and frequency, and establishing acceptance and rejection criteria based on batch size.
制定此类计划的关键因素包括选择适当取样方法、确定样本量和频率，以及根据批量建立接受和拒绝标准。

Ensuring statistical confidence both within individual batches and across multiple batches through risk analysis is vital.
通过风险分析确保单个批次内和多个批次间的统计置信度至关重要。

In the pharmaceutical industry, the Z1.4 standard, recognized for its guidelines on attribute sampling, assists in determining sample sizes and acceptance criteria, integrating data integrity and regulatory compliance through specified sampling procedures and documentation practices.
在制药行业，Z1.4标准因其计数型取样指南而受认可，有助于确定样本量和接受标准，通过规定取样程序和文件实践整合数据完整性和法规合规。

Active Ingredients and Their Challenges
活性成分及其挑战

Active Pharmaceutical Ingredients (APIs) are vital components within pharmaceutical products, requiring meticulous attention during sampling due to their direct impact on drug efficacy and safety.
活性药物成分（API）是药品中的重要组成部分，由于直接影响药物有效性和安全性，取样时需要细致关注。

The variability inherent in different raw materials, such as powders, granules, or tablets, mandates the adoption of tailored sampling approaches to achieve representative results.
粉末、颗粒或片剂等不同原料固有的变异性，要求采用量身定制的取样方法以获得代表性结果。

For instance, skip-lot testing for APIs, albeit beneficial in reducing the testing frequency and costs, should only be contemplated within an established supplier qualification system conforming to industry standards and regulatory authority expectations.
例如，API的跳批检测虽然有助于降低检测频率和成本，但只应在符合行业标准和监管机构期望的既定供应商资质确认体系内考虑。

Microbiological examination of APIs is another critical challenge, necessitating sampling under strictly controlled and sterilized conditions to avert contamination risks.
API的微生物检查是另一个关键挑战，需要在严格控制和灭菌条件下取样，以避免污染风险。

This separate microbiological sampling process ensures that APIs maintain their intended medicinal properties without exposing patients to health risks.
这一单独的微生物取样过程确保 API 维持其预期药用特性，而不使患者暴露于健康风险。

As these components often dictate the therapeutic effects, ensuring the highest quality standards through rigorous testing and validated sampling plans is crucial.
由于这些成分通常决定治疗效果，通过严格检测和经验证的取样计划确保最高质量标准至关重要。

Proper management of APIs during sampling, alongside supplier coordination and regulatory compliance, underpins successful pharmaceutical manufacturing.
取样期间对API的适当管理，加上供应商协调和法规合规，是成功制药生产的基础。

Packaging Materials and Their Specificities
包装材料及其特殊性

Packaging materials play a crucial role in safeguarding pharmaceutical products by ensuring stability, labeling accuracy, and regulatory compliance.
包装材料通过确保稳定性、标签准确性和法规合规，在保护药品方面发挥关键作用。

The primary packaging, which directly contacts the product, includes items like bottles, blister strips, and pouches, and must be tested for its quality and GMP adherence.
直接接触产品的一级包装包括瓶、泡罩条和袋等，必须检测其质量和GMP遵守情况。

Proper labeling and conformity to regulatory requirements are vital for primary packaging to ensure product integrity from manufacturing through to consumer use.
适当的标签和符合法规要求对一级包装至关重要，以确保从制造到消费者使用过程中的产品完整性。

Sampling plans tailored for these materials should focus on both their structural qualities and labeling precision to fulfill regulatory issued guidelines.
针对这些材料量身定制的取样计划应关注其结构质量和标签精确性，以满足监管发布的指南。

Secondary packaging, while it does not come into direct contact with the drug, provides important protection against external influences and must align with Good Manufacturing Practice data and product representation requirements.
二级包装虽然不直接接触药品，但提供防外部影响的重要保护，必须符合药品生产质量管理规范数据和产品表示要求。

Changes in materials, such as a switch from plastic to glass packaging, can necessitate revalidation processes due to their potential impact on product stability and safety.
材料变更，如从塑料包装转为玻璃包装，可能因对产品稳定性和安全性的潜在影响而需要再验证过程。

The guidance from health organizations such as the European Medicines Agency (EMA) aids in maintaining stringent regulatory compliance, stressing the importance of a methodical and adaptable approach in the sampling and testing of packaging materials.
欧洲药品管理局（EMA）等卫生组织的指南有助于维持严格法规合规，强调在包装材料取样和检测中采用有条理且适应性方法的重要性。

By upholding these standards, pharmaceutical manufacturers can ensure both compliance and consumer trust.
通过维护这些标准，制药生产商可以确保合规和消费者信任。

Integrating a Lifecycle Approach
整合生命周期方法

Integrating a lifecycle approach involves managing a product from its inception to its disposal in a way that maximizes efficiency and minimizes environmental impact.
整合生命周期方法涉及从产品诞生到处置进行管理，以最大化效率并最小化环境影响。

This approach is crucial in ensuring sustainability and continuous improvement within industries.
这种方法对于确保行业内的可持续性和持续改进至关重要。

Here are key components to consider:
以下是需要考虑的关键组成部分：

Design Phase: Initiate with sustainable design to ensure minimal resource use and waste generation.
设计阶段：以可持续设计开始，确保最少资源使用和废物产生。

Production: Employ efficient manufacturing processes, adhering to standards like ISO 9001, to ensure quality and compliance.
生产：采用高效制造过程，遵守ISO 9001等标准，以确保质量和合规。

Usage: Optimize product performance while minimizing energy consumption and waste during the product’s functional life.
使用：在产品功能寿命期间优化产品性能，同时最小化能耗和废物。

End of Life: Plan for recycling and disposal methods that reduce environmental impacts, in accordance with regulations.
生命末期：根据法规规划减少环境影响的回收和处置方法。

Benefits of a Lifecycle Approach:
生命周期方法的益处：

Enhanced resource management
增强资源管理

Reduced environmental footprint
减少环境足迹

Improved compliance with regulatory standards
改善符合监管标准

Challenges:
挑战：

Initial cost investments
初始成本投资

Complexity in implementation across entire lifecycle
整个生命周期实施的复杂性

By adopting a lifecycle approach, organizations not only improve their sustainability credentials but also meet increasing regulatory and consumer expectations for environmental stewardship.
通过采用生命周期方法，组织不仅改善其可持续性资质，还满足日益增加的监管和消费者对环境管理的期望。

Risk-Based Techniques in Sampling
取样中的基于风险技术

Risk-based techniques in sampling are essential in GMP (Good Manufacturing Practice) environments to ensure quality control is scientifically justified and statistically valid.
取样中的基于风险技术在药品生产质量管理规范（GMP）环境中至关重要，以确保质量控制科学合理且统计有效。

Employing methods like random and stratified sampling reduces biases and provides representative data critical for decision-making.
采用随机和分层取样等方法可减少偏倚，并提供对决策至关重要的代表性数据。

This approach is vital in minimizing risks associated with batch rejections or product recalls, assuring consistency and adherence to regulatory compliance.
这种方法对于最大限度降低批次拒绝或产品召回相关风险、确保一致性和遵守法规合规至关重要。

A robust sampling plan encompasses acceptance criteria and scientific justifications, aligning testing with regulatory guidelines such as those from the European Pharmacopoeia and the World Health Organization.
稳健取样计划包含接受标准和科学理由，使检测符合欧洲药典和世界卫生组织等监管指南。

Such plans mitigate potential failures in sample identification or handling, underscoring the importance of comprehensive risk management strategies.
此类计划减轻样品鉴别或处理中的潜在失败，强调全面风险管理策略的重要性。

Key Elements of Risk-Based Sampling Plans:
基于风险的取样计划的关键要素：

Methodologies: Utilize random and stratified sampling.
方法：利用随机和分层取样。

Outcomes: Prevent costly rejections or recalls.
结果：防止代价高昂的拒绝或召回。

Regulatory Compliance: Ensure alignment with guidelines.
法规合规：确保符合指南。

Data Integrity: Provide accurate, bias-free data.
数据完整性：提供准确、无偏数据。

By using these techniques, manufacturers can support regulatory expectations and maintain high standards for product quality, safeguarding both business interests and consumer safety.
通过使用这些技术，生产商可以支持监管期望并维持产品质量高标准，保护商业利益和消费者安全。

Process Validation in Sampling Procedures
取样程序中的工艺验证

Process validation is crucial in the pharmaceutical manufacturing industry to ensure that the manufacturing process consistently produces products that meet predetermined quality specifications.
工艺验证在制药生产行业中至关重要，以确保制造过程持续生产符合预定质量规格的产品。

This validation can be conducted on pilot-scale batches representing at least 10% of the production scale batch size, ensuring relevant insights into larger production processes.
该验证可在代表至少10%生产规模批量的中试规模批次上进行，确保对更大生产过程的相关见解。

A robust sampling plan is integral to process validation, supporting continuous improvement and effective risk management by guaranteeing product quality and consistency through scientifically justified procedures.
稳健取样计划是工艺验证不可或缺的一部分，通过科学合理程序保证产品质量和一致性，支持持续改进和有效风险管理。

This plan must align with regulatory standards set by authorities like the FDA, EMA, and ICH guidelines.
该计划必须符合FDA、EMA和ICH指南等权威机构制定的监管标准。

Key components of a sampling plan include:
取样计划的关键组成部分包括：

Sampling Method: Describes how samples are collected, ensuring randomness and representativeness.
取样方法：描述如何收集样品，确保随机性和代表性。

Sample Size: Determines the number of units tested to provide statistically significant data.
样本量：确定检测单位数量，以提供统计显著数据。

Sampling Frequency: Specifies how often samples should be taken.
取样频率：规定应多久取样一次。

Sampling Location: Identifies exact spots in the process where samples will be collected.
取样位置：识别过程中将收集样品的确切位置。

Acceptance Criteria: Defines the quality benchmarks samples must meet.
接受标准：定义样品必须满足的质量基准。

The following table summarizes essential sampling plan elements:
下表总结基本取样计划要素：

This detailed approach in process validation helps maintain data integrity and adherence to regulatory expectations.
工艺验证中的这种详细方法有助于维持数据完整性和遵守监管期望。

Necessary Tools for Effective Sampling
有效取样所需工具

Effective sampling in pharmaceutical manufacturing is pivotal for ensuring compliance with Good Manufacturing Practice (GMP) and achieving regulatory approval.
制药生产中的有效取样对于确保符合药品生产质量管理规范（GMP）和获得监管批准至关重要。

The process utilizes several indispensable tools and methods to maintain data integrity and quality assurance.
该过程利用若干不可或缺的工具和方法来维持数据完整性和质量保证。

Key Tools for Sampling:
取样的关键工具：

Sampling Methods: Techniques such as random, stratified, and composite sampling are crucial.
取样方法：随机、分层和混合取样等技术至关重要。

They ensure representative sampling that meets regulatory expectations.
它们确保符合监管期望的代表性取样。

Selection depends on material type and associated risk factors.
选择取决于物料类型和相关风险因素。

Statistical Models: Tools like ANSI/ASQ Z1.4 or ISO 2859 help determine the appropriate sample size and frequency, providing a statistically valid approach to quality assessment.
统计模型：ANSI/ASQ Z1.4 或 ISO 2859 等工具有助于确定适当样本量和频率，提供统计有效的质量评估方法。

Acceptance Criteria: Predefined limits or specifications outline the pass/fail conditions for raw materials, maintaining consistent quality standards.
接受标准：预定义限度或规格概述原料的通过/失败条件，维持一致质量标准。

Standard Operating Procedures (SOPs): These define the step-by-step sampling procedures to ensure uniformity and compliance with regulatory and internal quality standards.
标准操作程序（SOP）：这些定义逐步取样程序，以确保一致性和符合监管及内部质量标准。

Supporting Regulations: Guidelines from regulatory authorities, such as the European Pharmacopoeia and World Health Organization, inform specific sampling requirements.
支持法规：欧洲药典和世界卫生组织等监管机构的指南为具体取样要求提供信息。

These tools, combined with a scientific or risk-based rationale, are essential in creating a robust sampling plan that accurately represents raw materials across various stages of pharmaceutical manufacturing.
这些工具结合科学或基于风险的理由，对于创建稳健取样计划至关重要，该计划准确代表制药生产各阶段的原料。

Designing and Utilizing Sampling Booths
设计与使用取样间

Designing and utilizing sampling booths, or cleanroom sampling booths, is crucial for maintaining the integrity of pharmaceutical raw materials.
设计与使用取样间或洁净室取样间，对于维持制药原料完整性至关重要。

These booths provide a controlled environment to minimize contamination during the sampling process, a key compliance requirement under cGMP regulations.
这些取样间提供受控环境，以在取样过程中最大限度减少污染，这是cGMP法规下的关键合规要求。

Regulatory bodies like the FDA and EMA stress the importance of documented, scientifically justified sampling plans to ensure samples are representative and handled correctly.
FDA和EMA等监管机构强调记录完善、科学合理的取样计划的重要性，以确保样品具有代表性并得到正确处理。

A well-designed sampling booth incorporates equipment such as sterile bottles, pipettes, and thief scoops.
设计良好的取样间纳入无菌瓶、移液管和取样探子等设备。

These tools are essential for executing effective sampling procedures.
这些工具对于执行有效取样程序至关重要。

Additionally, the booth itself must support data integrity and assist in identity testing, ensuring raw materials meet specified Acceptance Criteria.
此外，取样间本身必须支持数据完整性并协助鉴别检测，确保原料符合规定接受标准。

Here’s a list of key features for an effective sampling booth design:
以下是有效取样间设计的关键特征列表：

Controlled Airflow: Maintains sterility and prevents external contamination.
受控气流：维持无菌并防止外部污染。

Ergonomic Design: Facilitates easy access to sampling materials.
人体工程学设计：便于轻松获取取样材料。

Documented Procedures: Align with Standard Operating Procedures (SOPs) for consistent sampling.
记录程序：与标准操作程序（SOP）一致，以实现一致取样。

Proper sampling booth utilization is part of a broader strategy aligning with industry standards such as ISO 2859 and regulatory guidelines, ensuring high-quality pharmaceutical manufacturing.
正确使用取样间是更广泛策略的一部分，符合ISO 2859等行业标准和监管指南，确保高质量制药生产。

Techniques to Maintain Material Integrity
维持物料完整性的技术

Maintaining material integrity during sampling in GMP manufacturing is pivotal for ensuring the quality of raw materials and components in the pharmaceutical industry.
在GMP生产中取样期间维持物料完整性，对于确保制药行业原料和组件质量至关重要。

A critical aspect is the identity testing of each container's contents, which is typically mandated by EU GMP guidelines to uphold material integrity.
一个关键方面是对每个容器内容物进行鉴别检测，欧盟GMP指南通常要求这样做以维护物料完整性。

A robust sampling strategy hinges on scientifically justified procedures and statistically valid sampling plans.
稳健取样策略取决于科学合理程序和统计有效取样计划。

This ensures that quality control activities within a GMP quality management system are efficient and maintain material integrity.
这确保GMP质量管理体系内的质量控制活动高效并维持物料完整性。

Composite sampling is a widely adopted technique where samples from multiple containers are pooled for analysis.
混合取样是一种广泛采用的技术，将来自多个容器的样品汇集进行分析。

This method helps in achieving consistency across tests and maintains the integrity of materials.
该方法有助于实现检测间一致性并维持物料完整性。

Regular assessment of composite samples through chemical analysis against pre-determined specifications is essential.
通过化学分析根据预定规格定期评估混合样品至关重要。

This process verifies the quality and consistency of GMP raw materials, helping to detect any deviations early on.
该过程验证GMP原料的质量和一致性，有助于及早检测任何偏差。

Key Techniques for Maintaining Material Integrity:
维持物料完整性的关键技术：

Identity Testing: Individual sample testing from all containers.
鉴别检测：对所有容器进行单独样品检测。

Composite Sampling: Pool sampling from various containers to ensure consistency.
混合取样：从各容器汇集取样以确保一致性。

Regular Chemical Analysis: Frequent assessments against specifications for verification.
定期化学分析：根据规格频繁评估以进行验证。

By employing these methods, manufacturers can uphold the expectations of regulatory authorities and maintain the integrity of raw materials in pharmaceutical manufacturing.
通过采用这些方法，生产商可以维护监管机构的期望并维持制药生产中原料的完整性。

Aligning Sampling Strategies with Regulatory Requirements
使取样策略符合法规要求

Aligning sampling strategies with regulatory requirements in GMP-regulated industries ensures scientifically justified and statistically valid quality control.
在GMP监管行业使取样策略符合法规要求，确保科学合理且统计有效的质量控制。

Meeting regulatory compliance involves adherence to FDA, EMA, and ICH guidelines, which form the backbone of a robust sampling plan for GMP raw materials.
满足法规合规涉及遵守FDA、EMA 和 ICH指南，这些指南构成 GMP 原料稳健取样计划的骨干。

The European Commission’s EudraLex Volume 4, Annex 8, specifically mandates identity testing for each container of starting material.
欧盟委员会 EudraLex 第4卷附录 8明确规定对每容器起始物料进行鉴别检测。

This requirement underscores the importance of individual sampling to ensure product safety and efficacy.
该要求强调单独取样以确保产品安全性和有效性的重要性。

Similarly, the EMA guideline EMA/CHMP/CVMP/QWP/70278/2012-Rev1 emphasizes thorough process validation to guarantee controlled and consistent manufacturing practices.
同样，EMA 指南EMA/CHMP/CVMP/QWP/70278/2012-Rev1强调彻底工艺验证以保证受控和一致的制造实践。

To meet these requirements, written sampling plans must align with cGMP requirements.
为满足这些要求，书面取样计划必须符合cGMP要求。

These are typically encapsulated in a Standard Operating Procedure (SOP) which specifies inspection levels, sampling sizes, and acceptance limits.
这些通常包含在标准操作程序（SOP）中，规定检查水平、取样量和接受限度。

Here is a snapshot of a sampling plan:
以下是取样计划的简要概览：

Such detailed strategies ensure data integrity and compliance with quality standards, promoting safety and regulatory acceptance.
此类详细策略确保数据完整性和符合质量标准，促进安全性和监管接受。

Incorporating Quality Management Principles
纳入质量管理原则

Incorporating quality management principles is crucial for ensuring compliance and regulatory adherence in Good Manufacturing Practice (GMP) within the pharmaceutical industry.
纳入质量管理原则对于确保制药行业药品生产质量管理规范（GMP）中的合规和法规遵守至关重要。

A key aspect of these principles is the development of comprehensive sampling plans, crucial for maintaining the consistency and safety of pharmaceutical products.
这些原则的一个关键方面是制定全面取样计划，这对于维持药品一致性和安全性至关重要。

These plans form an integral part of documentation strategies designed to manage starting materials effectively and assure the identity of Active Pharmaceutical Ingredients and other ingredients in the manufacturing process.
这些计划构成文件策略的不可或缺部分，旨在有效管理起始物料并确保制造过程中活性药物成分和其他成分的鉴别。

Effective quality management involves crafting sampling plans that yield representative data.
有效质量管理涉及制定产生代表性数据的取样计划。

This data determines whether materials meet acceptance criteria for use.
该数据确定物料是否符合使用接受标准。

The process requires consideration of batch size and employs principles from standards like ISO 2859 to guide sampling procedures.
该过程需要考虑批量，并采用 ISO 2859 等标准的原则指导取样程序。

A typical sampling process might involve:
典型取样过程可能涉及：

Random Sampling: Ensuring each unit has an equal chance of being selected.
随机取样：确保每个单位有同等被选机会。

Lot-by-Lot Inspection: Evaluating each batch individually.
逐批检查：单独评估每批。

Identity Testing: Confirming the identity of raw materials.
鉴别检测：确认原料鉴别。

Furthermore, the principles drive process validation efforts, which involve repetitive testing under various conditions to confirm the process's ability to produce quality products.
此外，这些原则推动工艺验证工作，涉及在各种条件下重复检测，以确认过程生产优质产品的能力。

Ultimately, these quality management benchmarks uphold data integrity and align with regulatory expectations, ensuring safe and effective pharmaceutical manufacturing.
最终，这些质量管理基准维护数据完整性并符合监管期望，确保安全有效的制药生产。

Mitigating Risks in the Sampling Process
减轻取样过程中的风险

Mitigating risks in the sampling process for raw materials in GMP manufacturing requires a well-designed sampling plan.
在 GMP 生产中减轻原料取样过程风险需要设计良好的取样计划。

Key elements include the sampling method, sample size, frequency, location, and acceptance criteria.
关键要素包括取样方法、样本量、频率、位置和接受标准。

These ensure scientifically justified and statistically valid quality control activities, minimizing contamination risks.
这些确保科学合理且统计有效的质量控制活动，最大限度降低污染风险。

Aligning sampling plans with regulatory standards, such as those from the FDA and EMA, is crucial to ensure consistent product quality and reduce the likelihood of batch rejection or product recall.
使取样计划符合 FDA 和 EMA 等监管标准，对于确保一致产品质量并降低批次拒绝或产品召回可能性至关重要。

Incorporating a risk-based approach that includes random and stratified sampling can effectively reduce bias, resulting in more representative data collection.
纳入包括随机和分层取样的基于风险方法，可以有效减少偏倚，从而实现更具代表性的数据收集。

For active raw materials, each container must be sampled and tested individually unless the supplier is validated.
对于活性原料，除非供应商已经过验证，否则必须对每个容器单独取样和检测。

This thoroughness is crucial for ensuring identity and quality verification.
这种彻底性对于确保鉴别和质量验证至关重要。

To provide a clear overview:
为提供清晰概览：

By adhering to these components and aligning with standards, manufacturers can effectively mitigate risks within the sampling process.
通过遵守这些组成部分并符合标准，生产商可以有效减轻取样过程中的风险。

Ensuring Product Safety and Efficacy
确保产品安全与有效性

Ensuring product safety and efficacy in GMP-regulated industries hinges on the design of a statistically valid sampling plan.
在 GMP 监管行业中确保产品安全性和有效性，取决于统计有效取样计划的设计。

This involves careful consideration of the sampling method, sample size, and frequency to maintain compliance and reduce the risk of batch rejection or recalls.
这涉及仔细考虑取样方法、样本量和频率，以维持合规并降低批次拒绝或召回风险。

Compliance with Good Manufacturing Practice guidelines demands thorough identity testing of samples from all containers of starting materials, such as Active Pharmaceutical Ingredients.
符合药品生产质量管理规范指南要求对起始物料（如活性药物成分）所有容器的样品进行彻底鉴别检测。

This verification confirms batch identity, ensuring consistent product quality and safety.
该验证确认批次鉴别，确保一致产品质量和安全。

Implementing robust sampling procedures, including comprehensive process validation as seen in 3X sampling plans, helps assure that manufacturing processes remain stable and capable under various conditions.
实施稳健取样程序，包括如 3X 取样计划中所见的全面工艺验证，有助于确保制造过程在各种条件下保持稳定和能力。

Effective sampling plans address not only raw materials but also extend to primary packaging materials, helping to prevent health hazards and mitigate recall risks.
有效取样计划不仅处理原料，还延伸到一级包装材料，有助于防止健康危害并减轻召回风险。

Here’s a quick checklist for designing a statistically valid sampling plan:
以下是设计统计有效取样计划的快速检查清单：

Conduct Process Validation: Assure stability and capability of processes.
开展工艺验证：确保过程的稳定性和能力。

Follow Compliance Standards: Align with Regulatory Authority guidelines, such as ISO 2859.
遵循合规标准：符合监管机构指南，如 ISO 2859。

Perform Identity Testing: Verify identity across all containers.
执行鉴别检测：验证所有容器的鉴别。

Implement Rigorous Verification: Validate labeling and packaging to prevent potential hazards.
实施严格验证：验证标签和包装以防止潜在危害。

By adhering to these principles, companies can maintain high standards of safety and efficacy, building trust and minimizing costly disruptions.
通过遵守这些原则，公司可以维持高安全性和有效性标准，建立信任并最大限度减少代价高昂的中断。

Conclusion and Best Practices
结论与最佳实践

In conclusion, designing a statistically valid sampling plan for raw materials in GMP manufacturing is essential to meet both regulatory expectations and quality assurance goals.
总之，为 GMP 生产中的原料设计统计有效的取样计划，对于满足监管期望和质量保证目标至关重要。

Such plans must encompass key components like sampling method, sample size, sampling frequency, sampling location, and acceptance criteria.
此类计划必须包含取样方法、样本量、取样频率、取样位置和接受标准等关键组成部分。

These elements ensure that the sampling process is not only compliant with FDA, EMA, and ICH guidelines but also scientifically robust.
这些要素确保取样过程不仅符合 FDA、EMA 和 ICH 指南，而且科学稳健。

Best practices for an effective sampling plan include:
有效取样计划的最佳实践包括：

Define Clear Processes: Develop detailed Standard Operating Procedures (SOPs) for documentation and execution of sampling activities.
定义清晰流程：制定详细标准操作程序（SOP），用于取样活动的记录和执行。

Ensure Regulatory Compliance: Align sampling plans with accepted standards like ISO 2859 and follow guidelines from authoritative bodies such as the European Pharmacopoeia and WHO.
确保法规合规：使取样计划符合 ISO 2859 等公认标准，并遵循欧洲药典和 WHO 等权威机构指南。

Implement Random Sampling: Use randomized procedures to minimize bias and obtain representative samples of raw materials and Active Pharmaceutical Ingredients (APIs).
实施随机取样：使用随机化程序以最大限度减少偏倚，并获得原料和活性药物成分（API）的代表性样品。

Evaluate Sample Size and Frequency: Adjust based on batch size and criticality of the material, ensuring sufficient data for analysis.
评估样本量和频率：根据批量和物料关键性调整，确保有足够数据用于分析。

For successful implementation, integrate these strategies into your system designs to uphold data integrity and enhance product quality, ultimately reducing the risk of batch rejection or recall.
为成功实施，将这些策略整合到系统设计中，以维护数据完整性并提高产品质量，最终降低批次拒绝或召回风险。